News

The executive director of the Institute for Translational Research at UNT Health discussed how to increase representation of underrepresented groups in Alzheimer disease clinical trials. [WATCH TIME: 5 minutes]

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

At CTAD 2025, the senior vice president of medical and scientific relations at the Alzheimer's Association talked about how structured lifestyle interventions improved blood pressure and sleep in the U.S. POINTER study. [WATCH TIME: 4 minutes]

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer, enhancing treatment options for early-stage patients.

A Korean study reveals that adjusted MMSE thresholds significantly increase eligibility for anti-amyloid treatments, highlighting demographic disparities and safety concerns.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

Here's some of what is coming soon to NeurologyLive® this week.

At NSGC 2025, the research director at the Clinic for Special Children discussed the clinic’s approach to accelerating the diagnosis and treatment of spinal muscular atrophy. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

Neurology News Network for the week ending November 29, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

The director of the Les Turner ALS Center at Northwestern Medicine talked about his lab’s preclinical research on identifying genetic targets for neurodegenerative diseases. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

The medical director of the stroke recovery program at JFK Johnson Rehabilitation Institute at Hackensack Meridian Health discussed the role health insurance plays in stroke survivors receiving rehabilitation care. [WATCH TIME: 4 minutes]

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.